Table 1

Clinical features and B-cell subsets of 25 patients with primary Sjögren syndrome (pSS) according the American–European Consensus Group (AECG)

Patients with pSSAECG items*Immunosuppressive drugsBm2+Bm2′/eBm5+Bm5
IIIIIIIVVVI
1++++MTX 15 mg/week0.9
PDN 6 mg/day
2++++1.6
3++++4.3
4++++HCQ 400 mg/day5.0
5++++++5.4
6++++++5.6
7+++++6.0
8++++6.3
9+++++HCQ 400 mg/day7.6
10++++++HCQ 400 mg/day7.6
PDN 5 mg/day
11+++++7.6
12++++++7.7
13+++++7.8
14++++++PDN 7 mg/day8.4
15+++++9.1
16++++HCQ 400 mg/day9.6
17+++++9.6
18++++12.6
19+++++13.7
20++++HCQ 400 mg/day14.6
21++++++HCQ 400 mg/day16.0
22++++++16.3
23++++++18.8
24+++++29.6
25++++++35.2
  • *AECG items6: I, ocular symptoms; II, oral symptoms; III, objective ocular signs (Schirmer’s test ⩽5 mm in 5 min); IV, lip biopsy with focus score ⩾1; V, objective evidence of salivary gland involvement (unstimulated whole salivary flow ⩽1.5 ml in 15 min); VI, anti-SSA and/or anti-SSB. (+), item fulfilled; (−), item not fulfilled.

  • HCQ, hydroxychloroquine; MTX, methotrexate; PDN, prednisone.